

Protocol for Respiratory Syncytial Virus (RSV) Vaccine

1. What's New

- A. The West Coast Health Alliance (WCHA) is issuing immunization recommendations for the 2025-2026 respiratory virus season. These recommendations are informed by trusted national medical organizations, including [American Academy of Pediatrics](#) (AAP), the [American College of Obstetricians and Gynecologists](#) (ACOG), and the [American Academy of Family Physicians](#) (AAFP). The WCHA believes that all recommended immunizations should be accessible to the people of our states.

2. Immunization Protocol

- A. Administer a single lifetime dose, IM, RSV vaccine to all adults ages 75 years and older.
- B. Administer a single lifetime dose, IM, RSV vaccine to persons ages 50 through 74 years of age if they are at increased risk of severe RSV disease, as described in Section 4.
- C. Administer a single lifetime dose, IM, RSV vaccine to pregnant patients at 32-36 weeks gestational age.
- D. RSV vaccine may be given with all ACIP- and WCHA-recommended adult vaccinations, including COVID-19 vaccines.

3. Vaccine Schedule ¹

	RSV immunization
Pregnancy	32 through 36 weeks gestational age ¹
Adults	All \geq 75 years ² All 50 through 74 years with risk factors ^{2,3}

¹ Either immunization with nirsevimab/clesrovimab or **maternal RSV vaccination** is indicated to protect infants from severe RSV infection.

² Adult RSV immunization recommendations are currently for a single lifetime dose. Those who have previously received a dose do not need a second dose.

³ See **Section 4** for additional information on risk factors for severe RSV disease in adults 50-74 years.

4. Additional Considerations for Use

- A. For additional information on risk factors for severe RSV disease in adults 50 through 74 years of age, see: <https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html>.

5. Pregnancy and Lactation ²⁻⁴

- A. It is unknown if RSV vaccines are excreted in human milk.
- B. See current prescribing information additional considerations regarding pregnancy and lactation.

6. Warnings and Precautions ²⁻⁴

- A. Individuals with acute, moderate, or severe illness with or without fever should delay immunization until symptoms have improved.
- B. Individuals with an immunocompromising condition may experience a diminished immune response to the vaccine.

Protocol for Respiratory Syncytial Virus (RSV) Vaccine

- C. See current prescribing information for more details about warnings, precautions, formulation, and contents.

7. Contraindications ¹⁻³

- A. Severe allergic reaction (e.g., anaphylaxis) to a previous dose or to any vaccine component.
- B. See current prescribing information for details about contraindications.

8. Storage and Handling ¹⁻³

- A. Store medications according to [OAR 855-041-1036](#).
- B. See current prescribing information for additional details about storage and handling.

9. References

1. West Coast Health Alliance 2025-2026 Recommendations for Respiratory Vaccines. Available at: <https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/VACCINESIMMUNIZATION/GETTINGIMMUNIZED/Documents/2025-26-Respiratory-Virus-Vaccine-Recommendations.pdf>
2. Abrysvo™. [Package insert]. October 2023. <https://www.fda.gov/media/168889/download>
3. Arexvy™. [Package insert]. June 2024. <https://www.fda.gov/media/167805/download?attachment>
4. mRESVIA®. [Package insert]. October 2024. <https://www.fda.gov/media/179005/download?attachment>